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on day 112. One recipient is pregnant 9 months post transplant.
In summary, this regimen is well tolerated, without increased
TRM or GVHD, and supports engraftment with varied stem cell
sources despite risk factors for graft rejection. Lymphopenia in the
early post transplant period requires close vigilance and early
intervention for infection.
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FREQUENCY AND MAGNITUDE OF DOSE ADJUSTMENT OF IV BUSULFAN
IN TARGETED DOSING STRATEGY FOR PEDIATRIC ALLOGENEIC
TRANSPLANTATION
Grimley, M.S., Taylor, C., Wall, D.A. Texas Transplant Institute, San
Antonio, TX
Busulfan is an important therapuetic agent in pediatric allogeneic
transplantation. The recent introduction of IV busulfan (IV
Busulfex®, ESPpharma) has descreased the intra-and interpatient
dose variations associated with oral absorption and allows for
targeted therapy. Children have increased drug clearance and vary-
ing degrees of hepatic function both developmentally and associ-
ated with the underlying disorders for which they are being
treated. Because of this variability, ﬁrst dose pharmacokinetics
were perfomed on all of our patients to ensure the targeted AUC
was achieved. In a series of 85 consecutive children undergoing
allogeneic transplant at Methodist Children’s Hospital/Texas
Transplant Institute from June 2001 to October 2003, 45 children
received myeloablative doses of busulfan (0.8 mg/kg for patients
3-10 kgs; 1 mg/kg for patients 10 kgs till age 4 yrs; 0.8 mg/kg for
patients  4 yrs given every 6 hours for 16 doses) as part of a
busulfan/cyclophosphamide, busulfan/melphalan or busulfan/ﬂu-
darabine preparative regimen. 42/45 patients had their actual
weight used for dosing calculations. Adjusted IBW was used in 3
patients. All patients received dilantin for seizure prophylaxis. First
dose pharmcokinetics were performed by the Clinical Pharmoki-
netics Lab at Seattle Cancer Care Alliance, targetting an AUC of
900-1300 umol.min, with dose adjustments done starting with dose
7, if needed. Donor source was matched sibling donor bone mar-
row or cord blood in 10 and unrelated donor sources in 35 (2
marrow and 33 mismatched umbilical cord units). The median age
was 4.7 yrs (range 1 month to 17 years). Patients underwent
transplant for a variety of conditions: 12 AML, 5 CML, 1 JMML,
9 ALL, 1 lymphoma, 3 HLH, 10 primary immunodeﬁencies, 4
hematology disorders. No patients developed VOD. 32/33 patients
of patients who received a fully myeloabalative preparative regimen
engrafted. A targeted AUC (900-1300 umoles.min) was achieved
with initial dosing in 50% of the patients. However, many children
required dose adjustment to achieve the targeted AUC, mostly
dose escalation (see table). Given the variability of metabolism in
children, ﬁrst dose pharmacokintics are recommended. Addition-
ally, the starting dose in infants is lower than the currently recom-
mended dose.
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LARGE VOLUME LEUKAPHERESIS FOR AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL COLLECTION IN CHILDREN WEIGHTING LESS THAN
25 KG
Ginani, V.C.1, Cecyn, K.Z.2, Carvalho, M.L.2, Caram, E.1, Macedo,
C.R.P.D.1, Gordan, L.N.1, Gouveia, R.V.1, Bastos, E.M.S.C.1, Del-
buono, E.1, Lee, M.L.M.1, Oliveira, O.M.W.1, Vieira, M.J.1, Seixas,
M.T.3, Petrilli, A.S.1, Seber, A.1 1. Pediatric Oncology Institute-
GRAACC-UNIFESP, Sao Paulo, SP, Brazil; 2. Hematology and He-
matotherapy-UNIFESP, Sao Paulo, SP, Brazil; 3. Pathology Depart-
ment-UNIFESP, Sao Paulo, SP, Brazil
Peripheral blood stem cells (PBSC) are the most frequent source
of hematopoietic stem cells used to rescue patients from high-dose
chemotherapy. The theoretical advantages of PBSC collections are
decreased tumor contamination and faster hematological engraft-
ment after the transplant. Small children are usually not eligible for
such protocols due to little experience of most Hematotherapy
teams, poor venous access and concern with a large extracorporeal
volume. In large volume leukapheresis (LVL) three or more blood
volumes are processed in the same procedure. LVL is also war-
ranted in pediatric patients to decrease the number of procedures
and potentially decrease tumor contamination. Twenty-ﬁve pa-
tients underwent LVL using a Cobe Spectra® cell separator be-
tween 2000-2003. All had the circuit primed with irradiated, ﬁl-
tered and resuspended red blood cells. All patients needed a central
venous catheter placed for the procedure. During the procedure,
the patients received continuous IV infusion with 10% calcium
gluconate 2cc/kg, 10% magnesium sulfate 1 cc/kg, 19.1% potas-
sium chloride 0.3 mEq/kg/hr over four hours to decrease the
adverse effects of ADC infusion. They had vital signs, EKG and
O2 saturation continuously monitored. Patients were 13M:12F
with a median age of 3.5 years-of-age (1-10). The median weight
was 14 kg (8-24). Underlying diagnoses were neuroblastoma (21),
germ cell tumors (2), non-Hodgkin’s lymphoma (1) and alveolar
soft tissue sarcoma (1). The median number of procedures was 2
(1-4). The median total nucleated cell count/kg was 16 (5-66) and
CD34/kg 6 (0.6-71). In conclusion, LVL can be safely performed
in small children if vital signs are adequately monitored and elec-
trolytes are replaced and promptly corrected.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR THE TREATMENT
OF PEDIATRIC SOLID TUMORS IN BRAZIL
Castro, C.G.1, Seber, A.2, Mendes, W.3, Castro, H.C.4, Borsato, M.L.4,
Gregianin, L.J.1, Ginani, V.C.2, Barros, J.C.A.4, Petrilli, A.S.2, Bru-
netto, A.L.1 1. Pediatric Oncology Unit-Hospital de Clinicas, Porto
Alegre, RS, Brazil; 2. Pediatric Oncology Institute-GRAACC-
UNIFESP, Sao Paulo, SP, Brazil; 3. Department of Pediatrics-Hospital
A.C. Camargo, Sao Paulo, SP, Brazil; 4. Pediatric Hematology and
Bone Marrow Transplantation Unit-Santa Casa de Sao Paulo, Sao
Paulo, SP, Brazil
High-dose chemotherapy and autologous stem cell rescue can be
used in the treatment of poor prognosis responsive pediatric solid
tumors. Our objective is to describe the experience of four Brazil-
ian hematopoietic stem cell transplantation (HSCT) centers in
Table.
Disease
Age
(years) Source
Cell
dose
(TNC/kg)
Engraft-
ment GVHD
Hurler’s 1.5 BM 3.26  10 (8) donor 0
Langerhan’s 19 S BM 3.38  10 (8) donor Gr1-sk
Thalassemia 10 S BM 2.2  10 (8) BM-d;PB-
mixed
0
Evan’s 12 UCB4/6 1.3  10 (7) donor 0
Aplastic anemia 12 S PB 1.9  10 (10) donor Gr1-sk
Adrenoleukodystrophy 3 S PB 4.58  10 (8) donor 0
Sickle cell anemia 2 S BM 3.3  10 (8) donor 0
Aplastic anemia 20 S BM
5/6
4.2  10 (8) NA 0
Hemophagocytosis 3 S BM 3.7  10 (8) NA 0
Aplastic anemia 32 UCB5/6 2.02  10 (7) NA 0
sk  skin; s  sibling; d  donor; NA  Not available.
Table.
Age/
Weight
Starting
Dose
(mg/kg)
AUC
mol  min:
Median
(range)
Final
Dosing
(mg/kg):
Median
(range)
Percent of
Patients
Requiring
Dose
Adjustment
Dose
Increased/
Dose
Decreased
3-10 kg
(n  12) 0.8 1167 (825-1869) 0.93 (0.67-1.25) 50%-6/12 pts 41/22
10 kg-4 years
(n  11) 1 1142 (908-1518) 1 (0.76-1.25) 27%-3/11 21/12
>4 years
(n  22) 0.8 1089 (620-1827) 0.82 (0.57-1.25) 65%-15/23 111/42
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treating such patients. Sixty-three autologous HSCT were per-
formed from August, 1994 to September, 2003; 80% of them were
after 1999. Thirty-four patients were male (54%). The median age
was 7 years (1 to 23). The underlying diagnoses were neuroblas-
toma (24), Wilms’ tumor (10), Ewing’s Sarcoma (9), medulloblas-
toma/ central nervous system primitive neuroectodermal tumor
(8), germ cell tumors (6), rhabdomyosarcoma (5) and desmoplasic
small round cell tumor (1). Twenty-one patients with neuroblas-
toma, two with medulloblastoma (under 3 years of age) and one
with metastatic rhabdomyosarcoma were in ﬁrst remission. The
others were in second or third remission or had refractory disease
(39). Melphalan, etoposide and carboplatin was the conditioning
regimen used in 68% of the patients. The peripheral blood was the
source of stem cells in 72% of them. The overall and disease free
survival at four years were 39  8% and 33  7%, respectively.
The median survival was 22  6 months. The overall survival,
according to diagnosis, was 53  11% for neuroblastoma, 58 
16% for Wilms’ tumor, 33 16% for Ewing’s sarcoma, 58 19%
for medulloblastoma, 50  29% for germ cell tumors and 20 
18% for rhabdomyosarcoma. Relapse was the main cause of
death (21/63-32%). Nine patients (14%) died due to trans-
plant-related toxicity or infections. In conclusion, HSCT is
feasible but carries a high transplant-related mortality. A Brazilian
HSCT registry is being organized. National trials are warranted
for better indication and evaluation of the role of stem cell trans-
plantation in the treatment of high-risk or relapsed pediatric solid
tumors.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) IN PEDIATRIC
PATIENTS WITH ADVANCED HODGKIN’S LYMPHOMA (HL): THE ROLE
OF INTERFERON-ALPHA POST-TRANSPLANT
Petropoulos, D.1, Worth, L.L.1, Mullen, C.A.1, Lockhart, S.2, Ramirez,
I.1, Chan, K.W.1 1. MD Anderson Cancer Center, Houston, TX; 2.
Children’s Hospital of Austin, Austin, TX
Interferon alpha (IFN	) has known anti-proliferative and immu-
nomodulating effects and might enhance immunity for better con-
trol of any residual HL after SCT. Between May 1994 and August
2003 a total of 12 pediatric (8 males) patients with HL (8 NS, 2 LP,
1MC, 1 NSALCL) underwent autologous SCT in our center.
Their median age was 16 (range 11-20) years. The median interval
between diagnosis and transplant was 16 months (range 6mos-9 y).
All patients had received a median of 3 prior treatments (range 2-4)
and all but two additional involved-ﬁeld radiotherapy. Disease
status at the time of SCT was: PD (4 patients), SD (2), PR (4), and
CR(2). The conditioning regimens were BEAM (n 6), CBV (n
3), or other(n  3) The source of SC was autoBM in 2 cases and
autoPBSC in 10. All patients achieved ANC and PLT engraftment
after a median time of 10 (9-16) and 12 (11-31) days respectively.
Nine patients received IFNa immunotherapy when the ANC and
the platelet count exceeded 1,500 and 50,000 respectively. Three
did not, two due to rapidly progressive disease. Interferon-	 ad-
ministration was initiated at a dose of 0.5 million Units/m2 tiw
(Klingerman et al, Blood 1991,78: 3306) at a median of 49 days
post-transplant (range 33-127). Patients received IFN	 for 1 to 24
months (median 12 months post-transplant). Observed toxicity was
hematologic and constitutional, with escalation of dose and/or
frequency as permitted by toxicity. The median tolerated weekly
dose was 3.5(range 1.5-6.5) mU/m2. With a median follow-up of
41(range 2-113) months, nine patients are alive and well (two less
than a year post SCT). Of the 10 patients who received IFN	, nine
are alive with no evidence of disease. Three patients died: two from
rapidly progressive HL (did not receive IFN	) and one from
relapse following allogeneic BMT. One patient, who relapsed after
transplant, was treated with IFN	 and chemotherapy and remains
in remission 5 years later. In conclusion, IFN-	 administration to
pediatric patients following SCT for advanced HL is safe and may
confer survival advantage.
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS(PTS) WITH GE-
NETIC DISEASES: A CALL FOR PHYSICIANS FROM DEVELOPING COUN-
TRIES TO DISCUSS ABOUT STRATEGIES TO IMPROVE DIAGNOSIS AND
EARLY REFERRAL TO BMT CENTERS
Bonﬁm, C.M.S., Bitencourt, M.A., Setubal, D.C., Moreira, V.A.,
Lorenzato, C., Ruiz, J., Zanis Neto, J., de Medeiros, C.R., Pasquini, R.
BMT Center-Federal University of Parana, Curitiba, PR, Brazil
Background: Brazil is a huge Latin-American country with
many social and economic disparities and more than 3 million live
births every year. SCT for pts with genetic diseases (GD) has a
speciﬁc timing because engraftment of donor cells does not always
correlate with improved quality of life or survival. Material and
Methods: Between 10/79 and 09/03 more than 1400 SCT were
performed in our BMT Unit but only 51 pts had GD. Median age:
3yr (range: 0,1 to 22). Gender: F11/M40; Diagnoses: Dyskeratosis
Congenita (DC): 5pts;Diamond-Blackfan Anemia (DBA): 5pts;
Congenital Dyserythropoietic Anemia (DBA): 1pt; Amegakaryo-
cytic Purpura (AmegaP): 1pt; Hemoglobinopathies: 4pts; Kost-
mann Syndrome: 1pt; Wiskott-Aldrich syndrome (WAS): 7pts;
Severe Combined Immunodeﬁciency (SCID): 7pts; Histiocytoses:
1pt; Gaucher disease: 1pt; Mucopolysaccharidosis: 6pts (MPS-I:
3pts, MPS-III: 1pt, MPS-VI: 2pts); Adrenoleukodystrophy (CO-
CALD): 3pts; Globoid Cell Leukodystrophy (GLD-Krabbe): 1pt;
Osteopetrosis (OP): 8pts. Bone marrow (BM) was the stem cell
source for 30 HLA-identical siblings, 3 other related and 1 hap-
loidentical (mother). 17pts received an unrelated transplant (11CB,
6BM). Conditioning regimen: Chemotherapy only: 41pts, Chemo-
therapy TBI: 7pts. No conditioning regimen: 3pts. GVHD pro-
phylaxis: Csa was given to 47pts. Results: 48pts were evaluable for
engraftment and 10pts had primary graft failure (osteopetrosis:
6pts). Thirty-three pts (DBA: 3pts; Gaucher: 1pt; MPS: 3pts; OP:
2pts, DC: 5pts, Hemoglobinopathies: 4pts, SCID: 6pts, WAS:
5pts; COCALD: 2pts; AmegaP: 1pt Histiocytoses: 1pt) are alive 6
to 5688 days post-BMT (Median: 1377days). Four pts are alive
with an autologous recovery (OP: 2pts, Hemoglobinopathies:
2pts). All pts with storage disease that are alive improved or
stabilized their neurological function, except for 1pt with MPS-III.
Eighteen pts died (14pts before day100). GVHD or graft-failure
associated with infections was responsible for most deaths. Con-
clusion: Medical education to improve early diagnosis and referral
to specialized centers is the key to success in GD. This has to be
done together with the commitment from the health system in
each country to guarantee that all pts will be able to receive
adequate treatment despite their economic or social background. It
is urgent that developing countries work together with interna-
tional centers to improve diagnosis, data collection and speciﬁc
treatments in these rare diseases.
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR FA-
MILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Archambault, B.L., Driscoll, T.A., Stafford, L.A., Szabolcs, P., Kurtzberg,
J., Martin, P.L. Duke University Medical Center, Durham, NC
Background: Patients with Familial Erythrophagocytic Lym-
phohistiocytosis (FEL) or Hemophagocytic Lymphohistiocytosis
(HLH) die of progressive disease early in life. Allogeneic stem cell
transplantation may be curative. However, many children lack a
suitably matched living related or unrelated donor. This study
investigated the feasibility of substituting partially HLA-mis-
matched, banked unrelated-donor umbilical cord blood (UCB) as
an alternative source of hematopoietic stem cells for transplanta-
tion in children with FEL lacking traditional HLA matched stem
cell donors. Methods: Five infants with FEL, with a median age of
0.58 years, (range 0.33-0.98) received myeloablative doses of busul-
fan, cyclophosphamide and ATG followed by unrelated UCB
transplantation between 11/98 and 2/02. Patients were evaluated
for donor cell engraftment, toxicity and effects of this therapy on
the natural history of the disease. Patients did not receive any post
transplant intrathecal therapy. No radiation therapy was adminis-
tered at any time during therapy. Results: UCB donors mis-
matched at 1-2 HLA markers delivering a median cell dose of
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